Provided by Tiger Trade Technology Pte. Ltd.

Xeris Pharmaceuticals Inc

6.68
+0.10001.52%
Post-market: 6.680.00000.00%17:31 EST
Volume:1.07M
Turnover:7.08M
Market Cap:1.11B
PE:-63.99
High:6.69
Open:6.59
Low:6.57
Close:6.58
52wk High:10.08
52wk Low:3.58
Shares:165.92M
Float Shares:159.00M
Volume Ratio:0.48
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1044
EPS(LYR):-0.3736
ROE:-617.16%
ROA:2.88%
PB:-1287.31
PE(LYR):-17.88

Loading ...

Earning Preview: Xeris Pharmaceuticals Inc Q1 revenue is expected to increase by 41.71%, and institutional views are constructive

Earnings Agent
·
Feb 23

Xeris Biopharma Holdings Inc. published an update to their financial calendar

Reuters
·
Feb 17

Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026

THOMSON REUTERS
·
Feb 17

A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Updated 2025 Revenue Outlook

Simply Wall St.
·
Jan 18

Xeris Biopharma President and COO Kevin McCulloch Reports Disposal of Common Shares

Reuters
·
Jan 10

Xeris Biopharma Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 09

Xeris Biopharma Expects 2025 Revenue to Reach $292 Million

Reuters
·
Jan 08

Xeris Biopharma Holdings Inc - Expects 2025 Revenue of $292 Mln, Exceeding Guidance

THOMSON REUTERS
·
Jan 08

Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue

THOMSON REUTERS
·
Jan 08

Xeris Biopharma Holdings Inc. Officer John Patrick Shannon Jr. Reports Disposal of Common Shares

Reuters
·
Jan 07

Xeris Biopharma Officer Beth Hecht Reports Sale of Common Shares

Reuters
·
Jan 06

BRIEF-Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Jan 03

Xeris Biopharma Grants 181,550 Restricted Stock Units to New Employees

Reuters
·
Jan 03

Have Xeris Biopharma Holdings Insiders Been Selling Stock?

Simply Wall St.
·
Dec 22, 2025

Director John Johnson Reports Sale of Xeris Biopharma Holdings Inc. Common Shares

Reuters
·
Dec 20, 2025

Director Barbara-Jean Anne Bormann-Kennedy Sells Xeris Biopharma Holdings Inc. Common Shares

Reuters
·
Dec 16, 2025

Xeris Biopharma Initiated at Overweight by Barclays

Dow Jones
·
Dec 10, 2025

Barclays Initiates Xeris Biopharma Holdings at Overweight With $9 Price Target

MT Newswires Live
·
Dec 09, 2025

Xeris Biopharma Officer Beth Hecht Reports Disposal of Common Shares

Reuters
·
Dec 03, 2025

Xeris Biopharma Holdings Inc - Unit Receives Uspto Notice of Allowance for XP-8121 Patent

THOMSON REUTERS
·
Dec 01, 2025